Physician profile
Mazen Alsaqa
NPI 1982968244
$8,175.24
in general payments reported to CMS, 2019-2025
34 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,493 · 2020: $720 · 2021: $1,127 · 2022: $1,119 · 2023: $1,062 · 2024: $1,239 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,622 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,621.54 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,243.75 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $964.19 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $704.44 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $540.98 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $354.06 | 2019-2022 | |
| Lilly USA, LLC | $350.44 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.21 | 2019-2025 | Jardiance, Tradjenta |
| Astellas Pharma US INC | $270.86 | 2019-2023 | Veozah |
| Glaxosmithkline, LLC. | $235.47 | 2022-2025 | Bexsero, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $231.49 | 2019-2023 | Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.54 | 2019-2024 | Xifaxan, Trulance |
| Agios Pharmaceuticals, INC. | $137.22 | 2025 | Pyrukynd |
| Amarin Pharma, INC. | $134.41 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $127.09 | 2023-2024 | Voquezna |
| Sumitomo Pharma America, INC. | $126.38 | 2023-2025 | Gemtesa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $126.00 | 2023 | Opsumit, Uptravi |
| Tactile Systems Technology INC | $113.18 | 2025 | Flexitouch Plus, Nimbl |
| Novartis Pharmaceuticals Corporation | $112.10 | 2019-2023 | |
| Intra-Sana Laboratories | $111.71 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Bayer Healthcare Pharmaceuticals INC. | $97.44 | 2021-2022 | |
| Orapharma, A Division of Bausch Health US, LLC | $97.07 | 2024 | Arestin |
| Abbott Laboratories | $95.74 | 2021-2024 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $83.84 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $70.46 | 2019-2022 | |
| Exact Sciences Corporation | $43.13 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $40.68 | 2023-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $35.49 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.04 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.73 | 2019 | |
| Abbvie INC. | $23.75 | 2023 | Ubrelvy |
| Ardelyx, INC. | $21.88 | 2024 | Ibsrela |
| Cranial Technologies, INC | $19.24 | 2024 | Doc Band |
| Amneal Pharmaceuticals LLC | $16.49 | 2023 | Unithroid |
| Kowa Pharmaceuticals America, INC. | $13.74 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Alsaqa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.